Analyst Price Target is $4.00
▲ +400.63% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Achilles Therapeutics in the last 3 months. The average price target is $4.00, with a high forecast of $6.00 and a low forecast of $2.00. The average price target represents a 400.63% upside from the last price of $0.80.
Current Consensus is
Hold
The current consensus among 3 polled investment analysts is to hold stock in Achilles Therapeutics. This Hold consensus rating has held steady for over two years.
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Read More